Absence of BRAF gene mutation in non-melanoma skin tumors

Cell Cycle

Volumn 5, Issue 9, 2006, Pages 968-970

  Libra, Massimo ^a   Malaponte, Grazia ^a   Bevelacqua, Valentina ^a   Siciliano, Roberta ^a   Castrogiovanni, Paola ^a   Fulvi, Alberto ^a   Micali, Giuseppe ^a   Ligresti, Giovanni ^b   Mazzarino, Maria C ^a   Stivala, Franca ^a   Travali, Salvatore ^a   McCubrey, James A ^c  

^a UNIVERSITY OF CATANIA   (Italy)

^b CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^c EAST CAROLINA UNIVERSITY   (United States)

Author keywords

BCC; BRAF

Indexed keywords

B RAF KINASE;

ADULT; AGED; ARTICLE; BASAL CELL CARCINOMA; BRAF GENE; CONTROLLED STUDY; GENE; GENE MUTATION; GENETIC SCREENING; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MELANOMA; MUTATION; ONCOGENE RAS; SKIN TUMOR; TUMOR BIOPSY;

EID: 33646393280     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.5.9.2724     Document Type: Article

References (21)

1. Ko CB, Walton S, Keczkes K, Bury HP, Nicholson C. The emerging epidemic of skin cancer. Br J Dermatol 1994; 130:269-72.
2. The Royal College of Pathologists, Minimum dataset for the reporting of common skin cancers. In: Standards and Minimum Datasets for Reporting Cancers. London: Royal College of Pathologists, 2002:5-10.
3. Sloane JP. The value of typing basal cell carcinomas in predicting recurrence after surgical excision. Br J Dermatol 1977; 96:27-32.
4. Sexton M, Jones DB, Maloney ME. Histologic pattern analysis of basal cell carcinoma. Study of a series of 1039 consecutive neoplasms. J Am Acad Dermatol 1990; 23:1118-26.
5. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100:57-70.
6. Popp S, Waltering S, Herbst C, Moll I, Boukamp P. UV-Btype mutations and chromosomal imbalances indicate common pathways for the development of Merkel and skin squamous cell carcinomas. Int J Cancer 2002; 99:352-60.
7. van der Schroeff JG, Evers LM, Boot AJ, Bos JL. Ras oncogene mutations in basal cell carcinomas and squamous cell carcinomas of human skin. J Invest Dermatol 1990; 94:423-5.
8. Lieu FM, Yamanishi K, Konishi K, Kishimoto S, Yasuno H. Low incidence of Ha-ras oncogene mutations in human epidermal tumors. Cancer Lett 1991; 59:231-5.
9. Pierceall WE, Goldberg LH, Tainsky MA, Mukhopadhyay T, Ananthaswamy HN. Ras gene mutation and amplification in human nonmelanoma skin cancers. Mol Carcinog 1991; 4:196-202.
10. Campbell C, Quinn AG, Rees JL. Codon 12 Harvey-ras mutations are rare events in nonmelanoma human skin cancer. Br J Dermatol 1993; 128:111-4.
11. Wilke WW, Robinson RA, Kennard CD. H-ras-1 gene mutations in basal cell carcinoma: Automated direct sequencing of clinical specimens. Mod Pathol 1993; 6:15-9.
12. Spencer JM, Kahn SM, Jiang W, DeLeo VA, Weinstein IB. Activated ras genes occur in human actinic keratoses, premalignant precursors to squamous cell carcinomas. Arch Dermatol 1995; 131:796-800.
13. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W, Davis N, Dicks E, Ewing R, Floyd Y, Gray K, Hall S, Hawes R, Hughes J, Kosmidou V, Menzies A, Mould C, Parker A, Stevens C, Watt S, Hooper S, Wilson R, Jayatilake H, Gusterson BA, Cooper C, Shipley J, Hargrave D, Pritchard-Jones K, Maitland N, Chenevix-Trench G, Riggins GJ, Bigner DD, Palmieri G, Cossu A, Flanagan A, Nicholson A, Ho JWC, Leung SY, Yuen ST, Weber BL, Seigler HF, Darrow TL, Paterson H, Marais R, Marshall CJ, Wooster R, Stratton MR, Futreal PA. Mutations of the BRAF gene in human cancer. Nature 2002; 417:949-54.
14. Chang F, Steelman LS, Lee JT, Shelton JG, Navolanic PM, Blalock WL, Franklin RA, McCubrey JA. Signal transduction mediated by the Ras/Raf/MEK/ERK pathway from cytokine receptors to transcription factors: Potential targeting for therapeutic intervention. Leukemia 2003; 17:1263-93.
15. Chang F, Steelman LS, Shelton JG, Lee JT, Navolanic PM, Blalock WL, Franklin R, McCubrey JA. Regulation of cell cycle progression and apoptosis by the Ras/Raf/MEK/ERK pathway. Int J Oncol 2003; 22:469-80.
16. Libra M, Malaponte G, Navolanic PM, Gangemi P, Bevelacqua V, Proietti L, Bruni B, Stivala F, Mazzarino MC, Travail S, McCubrey JA. Analysis of BRAF mutation in primary and metastatic melanoma. Cell Cycle 2005; 4:1382-4.
17. Tsao H, Goel V, Wu H, Yang G, Haluska FG. Genetic interaction between NRAS and BRAF mutations and PTEN/MMAC1 inactivation in melanoma. J Invest Dermatol 2004; 122:337-41.
18. Yons JF, Wilhelm S, Hibner B, Bollag G. Discovery of a novel Raf kinase inhibitor. Endocr Relat Cancer 2001; 8:219-25.
19. Karasarides M, Chiloeches A, Hayward R, Niculescu-Duvaz D, Scanlon I, Friedlos F, Ogilvie L, Hedley D, Martin J, Marshall CJ, Springer CJ, Marais R. B-RAF is a therapeutic target in melanoma. Oncogene 2004; 23:6292-8.
20. Chudnovsky Y, Khavari PA, Adams AE. Melanoma genetics and the development of rational therapeutics. J Clin Invest 2005; 115:813-24.
21. Solit DB, Garraway LA, Pratilas CA, Sawai A, Getz G, Basso A, Ye Q, Lobo JM, She Y, Osman I, Golub TR, Sebolt-Leopold J, Sellers WR, Rosen N. BRAF mutation predicts sensitivity to MEK inhibition. Nature 2006; 439:358-62.